Ratio Therapeutics

Ratio Therapeutics will be at ESMO 2026 in Madrid, Oct. 23-27. Looking forward to connecting with colleagues across the oncology community and discussing the evolving role of precision radiopharmaceuticals in solid tumors. #ESMO26 #Radiopharma #Oncology

Ratio Therapeutics will be at EANM 2026 in Vienna, Oct. 17-21. We look forward to connecting with colleagues across the nuclear medicine and radiopharmaceutical communities. See you at EANM! #EANM26 #Radiopharmaceuticals

Revisit Ratio Therapeutics’ John Babich on the CareTalk Podcast discussing how targeted radiotherapy is changing cancer care and the potential of radiopharmaceuticals in oncology. Listen here: caretalkpodcast.com/listen/e…

Ratio Therapeutics CSO John Babich will join industry leaders at CHI’s Radioligand Therapy meeting tomorrow, Sept. 29 for a panel on what defines the next generation of RLTs. bit.ly/4heGiP2

Ratio CEO Jack Hoppin will present at the Oppenheimer Private Life Sciences Company Showcase September 29 at 10:15 a.m. ET. The virtual presentation will highlight Ratio’s approach to precision radiopharmaceuticals for solid tumors.

Ratio Therapeutics’ John Babich will present at the 10th International Conference on Immunotherapy Radiotherapy Combinations in NYC, Sept. 23–25. bit.ly/4rkVOw0

We’re excited to welcome Kenan Turnacioglu, Ph.D. to Ratio Therapeutics’ Board of Directors. His expertise across healthcare investing, biotech and oncology will be a valuable addition to our team. prn.to/46toAB6

Ratio Therapeutics’ Kimberly Adkins, Senior Director, Manufacturing, will speak at the TRP Supply Chain Summit on Sept. 17. Her session will explore robust GMP strategies for radiopharmaceutical manufacturing under 211 expectations. bit.ly/4xmIfNX

Ratio Therapeutics CEO Jack Hoppin will participate in the Oppenheimer 4th Annual Targeted Radiopharmaceutical Therapies in Oncology Summit on Sept. 17 in NYC. Jack will join the “Delivery Platforms – Miniproteins, Peptides, mAbs & More” panel at 10:35 a.m. ET.

Ratio Therapeutics’ John Babich will be presenting at the 37th International Austrian Nuclear Medicine Congress (OGNT) in Bad Ischl, Austria, September 18. congress.ognt.at/

Ratio Therapeutics has entered into a research collaboration and license agreement with RayzeBio to advance a novel #radiopharmaceutical program. prnewswire.com/news-releases…

Ratio Therapeutics will participate in the upcoming conferences in September. - September 8-11: WMIC - September 16-18: 37th OGNT Congress - September 23-25: WCMC - September 29: CHI’s Radioligand Therapies Meeting

Ratio Therapeutics is grateful to be featured on the @Nasdaq Tower in Times Square following the close of our $70M Series C financing! bit.ly/4bzLlpV #Radiopharmaceuticals #Radiopharma #Oncology

Ratio closed a $70 million Series C to advance its radiotherapeutics pipeline and expand manufacturing capabilities, supported by Duquesne Capital, BMS, Catalio Capital, Eli Lilly, and Wasatch Group. prn.to/4wEFSa0 #Radiopharmaceuticals #Radiopharma #Oncology

Radiopharma in 2026: what's held up, what hasn't, and what's next? Our CSO John Babich, Ph.D., joins fellow scientific leaders for a candid fireside chat on landscape signals and inflection points at #TRPUS2026, San Diego. targeted-radiopharma-us.com/ #Radiopharmaceuticals

Our CSO John Babich, PhD, joined the CareTalk Podcast to break down how Ratio's Trillium™ platform and Macropa™ chelator are engineering better pharmacokinetics into targeted radiotherapeutics. youtube.com/watch?v=IapGdLtE… #Radiopharmaceuticals #Radiopharma #Oncology

Ratio today announced that it has entered into a strategic supply agreement with PanTera, supporting Ratio's ongoing efforts to build a robust and scalable supply infrastructure for its radiopharmaceutical development programs. prnewswire.com/news-releases… #Radiopharma #News

In a new @XTalks interview, Ratio CCMO Scott Holbrook breaks down why shelf life, proximity to isotope supply, and last-mile logistics are make-or-break for next-gen radioligand therapies. xtalks.com/radiopharmaceutic… #Radiopharmaceuticals #Radiopharma #Oncology

The radiopharma field is moving from excitement into execution, and our CSO John Babich, Ph.D., shares what that means for the industry in @Labiotech_eu's ASCO 2026 roundup. labiotech.eu/trends-news/asc… #Radiopharmaceuticals #Radiopharma #ASCO2026 #Oncology

Ratio will be presenting two posters at #SNMMI2026 this week in LA! [Ac-225]RTX-2358 in Relapsed/Refractory Soft Tissue Sarcoma — ATLAS Study (MTA11-Screen 32, June 2, 11:30 AM) Novel Granzyme B targeting probes 64Cu-RTX-4001 & 64Cu-RTX-4002 (MTA04-Screen 36, May 31, 7 PM)